

PHARMExcel

Transforming Commercial Clinical Trial Delivery



Driven by its motto, 'Together we make it happen,' PHARMExcel embodies a commitment to collaborative success. It connects with primary care networks and the UK Clinical Research Network (UKCRFN) to deliver a wide range of trial support services from early-phase to post-marketing.

"We're small enough to care but large enough to deliver," says Yvanne Enever, founder and CEO of PHARMExcel. "We provide accessible, client-first support for the NHS and the commercial research sector, with the ultimate goal of improving patient health."



With over 30 years of experience in the field, Enever has established trusted partnerships and strong connections across the UK academic and bioscience sector, enabling PHARMExcel to pass on a wealth of resources and expertise to its sponsors and their clinical research teams. She has cultivated a purposedriven culture within the company based on four core values—honesty and integrity, transparency, unwavering commitment to quality, and effective teamwork and passion.

The CRO's values instil trust and transparency in relationships with clients, ensuring that clients are always well-informed about what they're paying for and what to expect. Quality is another cornerstone of the ISO 9001:2015 certified company, with a focus on adhering to rigorous metrics and tolerance limits.

PHARMExcel is built on the foundation of a team of competent and experienced operational experts. Positioning itself as an extension of its client, it prioritises round-table discussion with its sponsors proactively contributes to the decision-making process. Its dedication mirrors the passion of clients, driven by the same core values.

Active participation in early conversations with clients enables PHARMExcel to provide valuable insights to enhance the study's design and execution, influencing the best course of action. It also helps clients navigate regulatory hurdles and implement diversity and inclusion strategies in clinical trials to increase access for underrepresented communities. This ensures that clinical trials are more representative and that the outcomes benefit a broader range of patients.

An impactful collaboration with the University of Liverpool in a COVID-19 treatment intervention within a platform trial stands out as a significant success story. The partnership facilitated streamlined discussions regarding study outcomes among various stakeholders, including the sponsor, site representatives, statistical and data management teams, and laboratories.

Engaging early with the client, the PHARMExcel team assigned clear roles centred on effective study management and prompt trial delivery, enabling expedited trial setup within strict timelines. By fast-tracking approvals at every stage, it achieved the platform trial's quickest and most extensive recruitment rate.

"

PHARMExcel exemplifies a commitment to partnership, transparency and responsiveness that sets it apart in the highly competitive CRO landscape

Moving beyond the typical CRO role, PHARMExcel actively participates in initiatives aimed at supporting disease-specific research. Its contributions to organisations like the International Accrediting Organisation for Clinical Research and involvement in disease-specific initiatives like the UK CLIF that focuses on developing new treatments for liver cirrhosis and enhancing patient participation in liver clinical trials in the UK, reflects its dedication to making a meaningful impact in clinical research.

PHARMExcel exemplifies a commitment to partnership, transparency, and innovation that sets it apart in the highly competitive CRO landscape. Possessing a deep understanding of the UK healthcare ecosystem and a passion for making a difference in the industry across the globe, it is a driving force in the world of clinical research, positively influencing the sector and delivering excellence in every trial.